Difficulty: Medium
Average Score: 72%
Practice
An otherwise healthy 18-year-old female is diagnosed with high-risk neuroblastoma after presenting with fatigue and bony pain. Imaging findings demonstrate a left adrenal mass with multiple osseous metastases. She successfully completes standard therapy for high-risk neuroblastoma, but experiences several episodes of disease recurrence and ultimately dies of her disease 10 years after her initial diagnosis. During her treatment, her tumor was sent for molecular analysis. Of the following, what molecular aberration was most likely to have been detected?
Correct answer
C
Rationale
Inactivating mutations in the ATRX chromatin remodeling gene are found in 14% of patients with high-risk neuroblastoma and in 44% of adolescent and adult patients with metastatic neuroblastoma. In addition to the association with older age at diagnosis, this mutation is associated with an indolent disease course and poor overall survival, as is seen in this patient's case. ETV6-NTRK3 gene fusions are characteristic of infantile fibrosarcoma and cellular congenital mesoblastic nephroma. Although NTRK aberrations can be seen in neuroblastoma, this specific fusion product is not. PTPN11 mutations are seen in neuroblastoma, particularly in patients with a germline mutation and phenotypic evidence of Noonan's syndrome. These mutations are also not associated with older age or an indolent disease course. WT1 mutations are not associated with neuroblastoma. MYCN amplification is incorrect because the incidence of MYCN amplification is low in older patients with neuroblastoma (approximately 3%), whereas the incidence of ATRX mutations is higher. Of note, ATRX mutations are mutually exclusive of MYCN amplification in neuroblastoma.